Skip to main content

An advanced prostate cancer clinical trial - PR25

A study for advanced prostate cancer patients with alterations in genes that repair damaged DNA
Disease Site
Genito-Urinary Clinical Trials
Trial Code
PR.25 ǀ NCT06439225
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to compare the effects on you and your prostate cancer of a new drug compared to other drugs which are the current standard treatment for this disease. The addition of the new drug to standard treatment could prevent your prostate cancer from progressing, but this cannot be known for sure. This study will help doctors find out if this different approach is better than the usual one.

Why is this study important?

The new drug being studied is a chemotherapy drug that has been used to treat other types of cancer, but it has not been studied in prostate cancer yet. Laboratory tests and clinical trials for other types of cancer have shown that it can help stop cancer from progressing in patients with alterations in genes that repair damaged DNA, but it is not clear if it can offer better results than standard treatment for prostate cancer.

Who can participate in this study?

This trial is for:

  • Patients with advanced prostate cancer
  • Patients whose cancer progressed after treatment with Androgen Pathway Receptor Inhibitors (ARPI)
  • Patients who have been medically or surgically castrated
  • Patients with alterations in genes that help repair damaged DNA

This trial is not for:

  • Patients who previously took a drug similar to the one being studied here
  • Patients who still have serious side effects from previous cancer treatment
  • Patients with blood cancers
  • Patients whose cancer has spread to their brain and is causing symptoms
What are the risks?
  • If you choose to take part in this study, there is a risk that the new drug may not be as good as the standard treatment at shrinking or stabilizing your prostate cancer. There is also a risk that you could have side effects from the combination of drugs being studied. Some of the most common side effects that the study doctors know about are: 
    • Nausea and vomiting 
    • Increased risk of infection 
    • Pain, burning, or tingling in the hands and feet 
    • Hair loss 
    • Fatigue
  • You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of two groups and you will receive either the new drug or another drug which is commonly used to treat advanced prostate cancer.
  • In this study, you will also be asked to complete a few questionnaires at different times to understand how treatment is affecting your quality of life.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The PR.25 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit www.clinicaltrials.gov and search using NCT06439225.

Use this trial information for your conversation with your health care team

Participating centres
  • Cross Cancer Institute - Edmonton, AB, T6G 1Z2 - Contact: Dr. Michael Kolinsky